Adaptin Bio (APTN) Gains from Investment Securities (2024 - 2026)

Adaptin Bio has disclosed Gains from Investment Securities across 3 years of filings, most recently posting $50000.0 for Q1 2026.

• Quarterly Gains from Investment Securities rose 692.14% year-over-year to $50000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $247906.0 (up 965.53% YoY) and the FY2025 annual result came in at $54923.0, up 221.43% from the prior year.
• Gains from Investment Securities retreated to $50000.0 in Q1 2026, from $109846.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $109846.0 in Q3 2025 and bottomed at $133.0 in Q1 2024.
• The 3-year median for Gains from Investment Securities is $6312.0 (2025), against an average of $26177.9.
• Year-over-year, Gains from Investment Securities jumped 4645.86% in 2025 and surged 692.14% in 2026.
• Adaptin Bio's Gains from Investment Securities stood at $8332.0 in 2024, then surged by 1218.36% to $109846.0 in 2025, then slumped by 54.48% to $50000.0 in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $50000.0, $109846.0, and $6312.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.